Nebula Research & Development LLC Makes New Investment in Castle Biosciences, Inc. (NASDAQ:CSTL)

Nebula Research & Development LLC bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,674 shares of the company’s stock, valued at approximately $711,000. Nebula Research & Development LLC owned 0.10% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP acquired a new position in shares of Castle Biosciences in the 4th quarter valued at $19,244,000. Renaissance Technologies LLC grew its holdings in shares of Castle Biosciences by 39.9% in the 4th quarter. Renaissance Technologies LLC now owns 685,000 shares of the company’s stock valued at $18,255,000 after buying an additional 195,438 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Castle Biosciences by 15.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 999,466 shares of the company’s stock valued at $26,636,000 after buying an additional 134,645 shares during the period. Vanguard Group Inc. grew its holdings in shares of Castle Biosciences by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company’s stock valued at $48,837,000 after buying an additional 83,783 shares during the period. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Castle Biosciences in the 4th quarter valued at $1,959,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Trading Down 2.6 %

CSTL opened at $20.09 on Tuesday. The firm’s fifty day simple moving average is $20.90 and its 200 day simple moving average is $26.48. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The stock has a market capitalization of $579.50 million, a P/E ratio of 100.46 and a beta of 1.11.

Insiders Place Their Bets

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Derek J. Maetzold sold 2,130 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the sale, the insider now directly owns 78,335 shares in the company, valued at $1,529,099.20. This trade represents a 2.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,321 shares of company stock valued at $774,644 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CSTL has been the subject of several research analyst reports. Stephens reissued an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Robert W. Baird boosted their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Finally, Guggenheim set a $30.00 price objective on shares of Castle Biosciences and gave the company a “buy” rating in a research report on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences has an average rating of “Buy” and an average price target of $38.75.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.